Genmab

Genmab A/S
Company typePublic
Nasdaq Copenhagen: GMAB
Nasdaq: GMAB (ADR)
OMX Copenhagen 25 component[1]
IndustryBiotechnology
Founded1999; 25 years ago (1999)
FounderFlorian Schönharting[2][3][4] and Lisa Drakeman[5]
HeadquartersCopenhagen, Denmark
Number of locations
4 (2023)[6]
Key people
ProductsDARZALEX/
DARZALEX FASPRO
EPKINLY/TEPKINLY
Kesimpta
RYBREVANT
TALVEY
TECVAYLI
TEPEZZA
Tivdak
RevenueDKK 16.474 billion (2023)[6]
DKK 5.321 billion (2023)[6]
DKK 4.352 billion (2023)[6]
Number of employees
2,204 (2023)[6]
WebsiteGenmab.com

Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund.[7] The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, USA, and Genmab K.K. in Tokyo, Japan. Genmab is a dual-listed company with shares traded on both the Copenhagen Stock Exchange in Denmark[8] and the NASDAQ Global Select Market in the US.[9]

  1. ^ "OMX Copenhagen 25 index info".
  2. ^ "Biotekstjerne spottede de gode forretninger". Berlingske. 20 October 2018. Retrieved 14 November 2020.
  3. ^ "Marketscreener". Marketscrenner. Marketscreener. Retrieved 14 November 2020.
  4. ^ "Forward Pharma Board Members". Forward Pharma. Retrieved 14 November 2020.
  5. ^ Cite error: The named reference Life Science Leader 2019 was invoked but never defined (see the help page).
  6. ^ a b c d e f Cite error: The named reference AR2023 was invoked but never defined (see the help page).
  7. ^ Form 8-K Current Report (Form 8-K). US Securities and Exchange Commission. March 5, 1999. Contacts. Retrieved 6 January 2020.
  8. ^ "GMAB, Genmab, (DK0010272202)" (Dynamic webpage). Nasdaq Nordic Ltd. Retrieved 9 March 2022. Market: Nasdaq Copenhagen
  9. ^ "Genmab A/S ADS (GMAB)" (Dynamic webpage). Nasdaq Inc. Retrieved 9 March 2022. Market: Nasdaq